Precision Neuromodulation for Stroke Recovery
Stroke
Pre-clinicalActive
Key Facts
About Panaxium
Panaxium is pioneering a novel therapeutic approach to neuro-recovery following brain injury. Its platform integrates a soft, biocompatible 'iontronic' brain-machine interface designed to communicate precisely with neural tissue, alongside advanced neuroimaging and AI to map patient-specific functional networks and plan interventions. The company is in the preclinical to early clinical stage, having secured non-dilutive funding and strategic partnerships, with the goal of turning everyday activities into assisted recovery exercises. Its vision is to move beyond symptom management to enable true healing and restoration of function.
View full company profileTherapeutic Areas
Other Stroke Drugs
| Drug | Company | Phase |
|---|---|---|
| NOX4 Inhibitor Platform | Glucox Biotech | Research |
| LG3 | Stream Biomedical | Pre-clinical |
| Patient Transport Optimization | Zeto | Research |
| NA-911 | Biomed | Phase 2A |
| DIASTROKE | Diagenics | Development/Commercial |
| APOSEC | Aposcience | Pre-clinical |
| NXL-001 | NeuExcell Therapeutics | Phase 1 |
| Autologous Wnt-activated ADSC Therapy | Regeneration Biomedical | Pre-clinical |
| NaviFUS Neuromodulation for Stroke Rehabilitation | NaviFUS | Phase 1 |
| Banked Cord Blood Stem Cells | Cryo-Cell | Clinical Trials |